Powered by Roundtable

What It Does: NextEra Energy operates Florida Power & Light and NextEra Energy Resources, making it the largest wind and solar utility in the United States. The company operates 32 GW of renewable capacity and has contracts to double this by 2030. Data center operators desperately need reliable renewable power: Google, Meta, and Microsoft have made net-zero commitments, driving demand for NextEra's wind and solar projects. NextEra Energy Partners (NEP, a Master Limited Partnership) offers investors yields from long-term power purchase agreements (PPAs) with investment-grade creditworthy offtakers. NEE generated $72B in operating revenue in FY2024, with 60%+ from regulated utility operations (stable, predictable cash flows). The renewable buildout accelerates free cash flow growth to 7%+ annually through 2027.

How the Stock Looks: NEE trades near $75 with a market cap of $155 billion. The stock has underperformed broader equities in the past year, facing interest rate headwinds (utilities are rate-sensitive) and earnings stagnation from regulatory constraints. The dividend yield is 2.3%, with coverage ratios healthy. Free cash flow tops $8B annually, funding capex and dividends. Valuation at 23x forward earnings appears reasonable given growth prospects, but equity investors have rotated to higher-yielding alternatives. Key catalysts include quarterly renewable project completions, PPA announcement commentary, data center power deal progress, and dividend growth announcements.

What Analysts Are Saying: 26 analysts rate NEE a Buy, with consensus price target of $85. Bullish analysts from Goldman Sachs and KeyBanc emphasize the secular renewable energy tailwind and data center power contracting acceleration. Regulatory tailwinds—clean energy incentives and grid modernization spending—support valuation. Bears at Credit Suisse cite regulatory uncertainty and rising interest rate sensitivity. However, consensus is constructive: the data center renewable power narrative is compelling, and NEE's contracted cash flows provide downside protection. The stock is a long-term compounder for patient capital.